ONCODES.PREC.MED. EO-34 (F:ZR8) — Market Cap & Net Worth
Market Cap & Net Worth: ONCODES.PREC.MED. EO-34 (ZR8)
ONCODES.PREC.MED. EO-34 (F:ZR8) has a market capitalization of $5.17 Million (€4.42 Million) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #28607 globally and #2466 in its home market, demonstrating a 6.42% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ONCODES.PREC.MED. EO-34's stock price €0.23 by its total outstanding shares 19067385 (19.07 Million). Also see ZR8 asset base for a full breakdown of the balance sheet.
ONCODES.PREC.MED. EO-34 Market Cap History: 2022 to 2026
ONCODES.PREC.MED. EO-34's market capitalization history from 2022 to 2026. Data shows change from $40.01 Million to $5.17 Million (-41.08% CAGR).
ONCODES.PREC.MED. EO-34 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ONCODES.PREC.MED. EO-34's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ZR8 stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
77.74x
ONCODES.PREC.MED. EO-34's market cap is 77.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $40.01 Million | $7.98 Million | -$231.18K | 5.01x | N/A |
| 2023 | $38.45 Million | $1.07 Million | -$8.09 Million | 35.86x | N/A |
| 2024 | $16.09 Million | $207.04K | -$7.21 Million | 77.74x | N/A |
Competitor Companies of ZR8 by Market Capitalization
Companies near ONCODES.PREC.MED. EO-34 in the global market cap rankings as of September 19, 2026. Review how tangible is ONCODES.PREC.MED. EO-34's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ONCODES.PREC.MED. EO-34 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
ONCODES.PREC.MED. EO-34 Historical Marketcap From 2022 to 2026
Between 2022 and today, ONCODES.PREC.MED. EO-34's market cap moved from $40.01 Million to $ 5.17 Million, with a yearly change of -41.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €5.17 Million | -35.73% |
| 2025 | €8.05 Million | -50.00% |
| 2024 | €16.09 Million | -58.14% |
| 2023 | €38.45 Million | -3.90% |
| 2022 | €40.01 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of ONCODES.PREC.MED. EO-34 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.17 Million USD |
| MoneyControl | $5.17 Million USD |
| MarketWatch | $5.17 Million USD |
| marketcap.company | $5.17 Million USD |
| Reuters | $5.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ONCODES.PREC.MED. EO-34
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a rad… Read more